FATE vs IDXX · rev $3.4M vs P/E 40, rev $2.36B
Fate Therapeutics Inc (FATE) versus IDEXX Laboratories Inc (IDXX) — a side-by-side from cached financials, not a winner call.
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Latest reported FATE revenue for 2026-06-30 was $3.4M. Net income was -$61.4M. FATE currently screens at market cap $331.0M.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
FATE currently screens at market cap $331.0M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Not investment advice. Open the FATE and IDXX stock pages for the full models.
Not investment advice.